Výsledky vyhledávání - "D A, Anzalone"

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group

Autor: R A, Rodby, R D, Rohde, W R, Clarke, L G, Hunsicker, D A, Anzalone, R C, Atkins, E, Ritz, E J, Lewis

Publikováno v: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 15(4)

Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world. Angiotensin-converting enzyme inhibitors have been demonstrated to be renoprotective in type I diabetes and are now the standard of care for both hyperte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::06496d170af1f0eb4d72007af5df5124
https://pubmed.ncbi.nlm.nih.gov/10727543

Zobrazit plný text záznamu

Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group

Autor: E, Reisin, M R, Weir, B, Falkner, H G, Hutchinson, D A, Anzalone, M L, Tuck

Publikováno v: Hypertension (Dallas, Tex. : 1979). 30(1 Pt 1)

Because obesity-associated hypertension has unique hemodynamic and hormonal profiles, certain classes of antihypertensive agents may be more effective than others as monotherapy. Thus, we compared the efficacy and safety of the angiotensin-converting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::44651ffd2fbeddd0f4fc952ecce4f06e
https://pubmed.ncbi.nlm.nih.gov/9231834

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání